All In Biotech

Drug Trial Radar · NCT06679153

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

A Randomized, Double-masked, Active-controlled, Multi-center Phase 2 Clinical Study Evaluating the Efficacy and Safety of 0.5% and 1.0% VVN461 Ophthalmic Solution in Patients With Noninfectious Anterior Uveitis

Last checked: Nov 20, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

89

Actual

Start

Nov 27, 2023

Primary completion

Dec 29, 2024

Study completion Dec 29, 2024

Sponsor

Lead sponsor
VivaVision Biotech, IncIndustry
Sponsor type
Industry
First posted
Nov 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, double-masked, randomized, active-controlled, parallel-comparison study conducted at sites in the China in subjects with Noninfectious Anterior Uveitis

Conditions

  • Anterior Uveitis

Interventions

  • VVN461 Ophthalmic Solution 1.0%Drug

    VVN461 Ophthalmic Solution, 1.0%, for up to 28 days

  • VVN461 Ophthalmic Solution 0.5%Drug

    VVN461 Ophthalmic Solution, 0.5%, for up to 28 days

  • Prednisolone acetateDrug

    Prednisolone acetate, 1%, for up to 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ACC score of ≥2 grade from baseline at Day 14Time frame: Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.